Jing-Yu Tan1, Lorna K P Suen1, Alex Molassiotis2. 1. School of Nursing, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong. 2. School of Nursing, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong. alex.molasiotis@polyu.edu.hk.
Abstract
PURPOSE: This paper aims to assess the psychometric properties of the Chinese version of the MASCC Antiemesis Tool (MAT) for measuring chemotherapy-induced nausea and vomiting (CINV). METHODS: This was a psychometric study using a panel of experts and a prospective observational design. Six experts were invited to identify the content validity and face validity of the MAT, and 115 cancer patients were then recruited from three provincial medical centers in Fuzhou, China. The MAT was self-completed by the patients on the first and the fifth day after receiving the most recent chemotherapy, and patients also rated daily the Index of Nausea, Vomiting, and Retching (INVR) during the first 5 days after chemotherapy. Content validity was measured by the index of the content validity (CVI). Construct validity was estimated by the contrasted groups approach. Concurrent validity was measured by exploring the correlations between the INVR and MAT scores. The reliability of the MAT was examined by Cronbach's alpha and item-to-total correlations. RESULTS: One hundred and eleven subjects returned the completed measures. High content validity was determined. Contrasted groups analysis clearly discriminated the differences on the CINV symptom experiences between different age and gender groups. Excellent concurrent validity was identified, with the Spearman's correlation coefficient between the MAT total score and the INVR overall total score of 0.94 (P < 0.001). Cronbach's alpha for the MAT was 0.73, and the item-to-total correlations ranged from 0.50 to 0.71. CONCLUSIONS: The MAT Chinese version is a valid, reliable, and convenient instrument for measuring CINV in Chinese cancer patients.
PURPOSE: This paper aims to assess the psychometric properties of the Chinese version of the MASCC Antiemesis Tool (MAT) for measuring chemotherapy-induced nausea and vomiting (CINV). METHODS: This was a psychometric study using a panel of experts and a prospective observational design. Six experts were invited to identify the content validity and face validity of the MAT, and 115 cancerpatients were then recruited from three provincial medical centers in Fuzhou, China. The MAT was self-completed by the patients on the first and the fifth day after receiving the most recent chemotherapy, and patients also rated daily the Index of Nausea, Vomiting, and Retching (INVR) during the first 5 days after chemotherapy. Content validity was measured by the index of the content validity (CVI). Construct validity was estimated by the contrasted groups approach. Concurrent validity was measured by exploring the correlations between the INVR and MAT scores. The reliability of the MAT was examined by Cronbach's alpha and item-to-total correlations. RESULTS: One hundred and eleven subjects returned the completed measures. High content validity was determined. Contrasted groups analysis clearly discriminated the differences on the CINV symptom experiences between different age and gender groups. Excellent concurrent validity was identified, with the Spearman's correlation coefficient between the MAT total score and the INVR overall total score of 0.94 (P < 0.001). Cronbach's alpha for the MAT was 0.73, and the item-to-total correlations ranged from 0.50 to 0.71. CONCLUSIONS: The MAT Chinese version is a valid, reliable, and convenient instrument for measuring CINV in Chinese cancerpatients.
Authors: Alexander Molassiotis; Matti Aapro; Mario Dicato; Pere Gascon; Sylvia A Novoa; Nicolas Isambert; Thomas A Burke; Anna Gu; Fausto Roila Journal: J Pain Symptom Manage Date: 2013-09-24 Impact factor: 3.612
Authors: A Molassiotis; M P Saunders; J Valle; G Wilson; P Lorigan; A Wardley; E Levine; R Cowan; J Loncaster; C Rittenberg Journal: Support Care Cancer Date: 2007-10-10 Impact factor: 3.603
Authors: Alexander Molassiotis; Wanda Russell; John Hughes; Matthew Breckons; Mari Lloyd-Williams; Janet Richardson; Claire Hulme; Sarah G Brearley; Malcolm Campbell; Adam Garrow; W David Ryder Journal: J Pain Symptom Manage Date: 2013-04-17 Impact factor: 3.612
Authors: Alexander Molassiotis; Peter A Coventry; Carrie T Stricker; Caroline Clements; Beth Eaby; Luke Velders; Cynthia Rittenberg; Richard J Gralla Journal: J Pain Symptom Manage Date: 2007-05-23 Impact factor: 3.612
Authors: Jing-Yu Tan; Alexander Molassiotis; Tao Wang; Lorna K P Suen Journal: Evid Based Complement Alternat Med Date: 2014-11-25 Impact factor: 2.629